Quantification of 11C-Laniquidar Kinetics in the Brain

Area of Science:

• Radiochemistry and Nuclear Medicine
• Pharmacokinetics and Drug Metabolism
• Molecular Imaging

Background:

• P-glycoprotein overexpression is linked to multidrug resistance.
• (11)C-laniquidar is a novel PET tracer for assessing P-glycoprotein expression.
• Accurate quantification of tracer kinetics is crucial for clinical applications.

Purpose of the Study:

• To develop a pharmacokinetic model for quantifying (11)C-laniquidar uptake in the brain.
• To evaluate the test-retest variability of the developed model.
• To optimize the analysis of (11)C-laniquidar PET data.

Main Methods:

• Two dynamic (11)C-laniquidar PET scans were performed in 8 healthy subjects.
• Plasma input functions were determined with metabolite correction.
• Time-activity curves were analyzed using compartmental models, including single-tissue compartment (1T1K) and dual-input models.

Main Results:

• (11)C-laniquidar undergoes rapid metabolism, with 50% parent plasma fraction at 10 min.
• A dual-input model provided a significantly better fit than the 1T1K model.
• Robust K1 values were obtained using the 1T1K model with the first 5 min of data and 60-min plasma input.
• Test-retest variability for the rate constant K1 was approximately 19% for both models.

Conclusions:

• Accurate quantification of (11)C-laniquidar brain kinetics is challenging due to rapid metabolism and metabolite brain entry.
• A dual-input model best describes the entire 60-min data, accounting for parent tracer and metabolites.
• Alternatively, K1 can be reliably estimated from a 5-min scan using the 1T1K model.
• The test-retest variability of K1 was consistent at approximately 19% across validated methods.